InBios International

Executive Summary

InBios International, a privately held diagnostics company based in Seattle, focuses on developing and commercializing rapid, point-of-care tests for infectious diseases with global health impact. With over 25 years of experience, the company addresses unmet needs in underserved regions, particularly for emerging pathogens like Chikungunya, which threatens 5.6 billion people across 119 countries. InBios' portfolio includes tests for viral and bacterial infections, leveraging proprietary platform technologies to deliver accurate, affordable, and easy-to-use diagnostics. The company is well-positioned to capitalize on growing demand for decentralized testing, especially in low-resource settings, and has potential to expand into multiplex panels and surveillance tools. Despite limited public visibility, InBios' longevity and niche focus suggest a resilient business model with room for growth as global health priorities evolve.

Upcoming Catalysts (preview)

• Q3 2026FDA 510(k) clearance for Chikungunya point-of-care test60% success
• Q2 2026Strategic partnership with global health organization for distribution in endemic countries70% success
• H2 2026Series A/B funding round to scale manufacturing and R&D50% success